Nav: Home

Cancer stem cells, allies of the tumor and enemies of the patient

March 05, 2018

The scientists of the UEx Molecular Biology of Cancer Research Group have a very clear objective. They want to uncover the physiological mechanisms of the cancer stem cell, the arch-enemy of the patient because it is responsible for the progression of the tumour. With that in mind, they are working on identifying new cell proteins which control cellular differentiation. Cancer stem cells possess the capacity to adopt highly undifferentiated states, characteristic of pluripotent cells, which very possibly contribute to the progression and maintenance of the different cells that form the tumour, in the same way that a healthy stem cell can give rise to different cell phenotypes. "These cancer stem cells are more resistant to the attack of chemotherapeutic agents, they are capable of regenerating the tumour and helping the tumour cells to spread to other organs", explains Pedro Fernández Salguero, lead researcher on the project.

The deregulation of cellular differentiation plays a very important role from an oncological point of view because it fosters the development of more undifferentiated and aggressive tumours, whose prognosis is worse. "Therefore, we want to identify which proteins within the cells are involved in retaining the undifferentiated characteristics of the tumour, which would allow it to be attacked more successfully, or, on the contrary, those leading to differentiated characteristics which reduce tumour development", adds Fernández Salguero.

The dioxin receptor, implicated in hepatocellular carcinoma and melanoma

One specific protein might contribute to keeping the tumour in a more highly undifferentiated state that could affect its metastatic capacity and its response to therapy. In fact, this group of researchers has already observed how a certain cell protein, the dioxin receptor (Ahr), participates in this process of cellular differentiation. "We have studied lines of cancer stem cells derived from patients and analysed tumour markers of potential clinical interest in animal models. The results obtained from both models have been validated in biopsies from patients with hepatocellular carcinoma and melanoma at the Infanta Cristina Hospital, in Badajoz (Spain). In this validation, the investigators found different values for this protein within the tumour and in the non-cancerous tissue from the same patients, and in turn, that the protein changes its expression in advanced stages, compared with stages prior to the development of the tumour (hepatic cirrhosis or hepatitis, in the case of hepatocellular carcinoma).

Thus, the results point to a therapeutic value for this protein (Ahr) because controlling it might repress the pluripotency of the cancer stem cell and reduce the malignity of the tumour. Indeed, different naturally-occurring molecules have been identified that modulate the activity of this protein in specific ways. In addition, the dioxin receptor might also facilitate the development of tools for the prognosis and evolution of the types of cancer in the study, hepatocellular carcinoma and melanoma.

Liver cancer

Hepatocellular carcinoma is a primary liver cancer, which is distinct from hepatic metastases originated by other tumours, highly aggressive and generally with poor prognosis. Further, its incidence is rising because this tumour usually appears as a consequence of an alcoholic liver cirrhosis or an infection by hepatitis B or C. At the moment, those suffering from liver cancer have few therapeutic opportunities, one of the few alternatives being a liver transplant. Tools for molecular prognosis and therapeutic targets are very scarce and the current survival rate for patients with advanced hepatocellular carcinoma is below 10%. As a consequence, it is necessary to identify new molecules and therapeutic options which complement the use of surgical resection and the transplant.
This investigation is part of the project "Role of dioxin receptor in pluripotency and reprogramming: novel mechanisms regulating tumour cell differentiation", financed by the Spanish National R+D+i Programme Directed at the Challenges of Society (SAF2014-51813-R). The collaborators are the Hepatic-Biliopancreatic Surgery and Pathological Anatomy Services of the Infanta Cristina University Hospital, and the Biomedical University Research Institute of Extremadura (INUBE), currently being created.

University of Extremadura

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...